Zhejiang Hisun Pharmaceutical Co.,Ltd.(600267),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

600267 Zhejiang Hisun Pharmaceutical Co.,Ltd.

Closed 10-22 15:00:00

13.66

-0.29

-2.08%

High13.94	Low13.56	Vol65.64M
Open13.92	D1 Closing13.95	Amplitude2.72%
Mkt Cap16.12B	Tradable Cap16.12B	Total Shares1.18B
T/O902.00M	T/O Rate5.56%	Tradable Shares1.18B
P/B1.79	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"600267","market":"SH","secType":"STK","nameCN":"Zhejiang Hisun Pharmaceutical Co.,Ltd.","latestPrice":13.66,"timestamp":1792652400000,"preClose":13.95,"halted":0,"volume":65638430,"delay":0,"changeRate":-0.0208,"floatShares":1180000000,"shares":1180000000,"eps":0.744,"marketStatus":"Closed","change":-0.29,"latestTime":"10-22 15:00:00","open":13.92,"high":13.94,"low":13.56,"amount":902000000,"amplitude":0.0272,"askPrice":13.67,"askSize":619,"bidPrice":13.66,"bidSize":503,"shortable":0,"etf":0,"ttmEps":0.744,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1792719000000},"marketStatusCode":5,"adr":0,"adjPreClose":13.95,"symbolType":"stock","openAndCloseTimeList":[[1792632600000,1792639800000],[1792645200000,1792652400000]],"highLimit":15.35,"lowLimit":12.56,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1180272096,"isCdr":false,"pbRate":1.79,"roa":"--","peRate":18.360215,"roe":"7.2%","epsLYR":0.46,"committee":-0.337496,"marketValue":16123000000,"turnoverRate":0.0556,"status":1,"floatMarketCap":16123000000},"requestUrl":"/m/hq/s/600267/wiki","defaultTab":"wiki","newsList":[{"id":"2675606215","title":"Zhejiang Hisun Pharmaceutical Sees 9-Month Net Profit up 149.46% Y/Y","url":"https://stock-news.laohu8.com/highlight/detail?id=2675606215","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675606215?lang=en_us&edition=fundamental","pubTime":"2026-10-16 17:14","pubTimestamp":1792142084,"startTime":"0","endTime":"0","summary":"BRIEF-Zhejiang Hisun Pharmaceutical Sees 9-Month Net Profit Up 149.46% Y/YOct 16 (Reuters)-Zhejiang Hisun Pharmaceutical Co Ltd600267.SS:SEES 9-MONTH NET PROFIT UP 149.46% Y/YSource textFurther company coverage:600267.SS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261016:nL4N4620R5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0028","BK0239","BK0060","600267"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667107366","title":"Hisun Pharmaceutical's Subsidiary Gets Nod for Topical Solution for Cat Infection","url":"https://stock-news.laohu8.com/highlight/detail?id=2667107366","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667107366?lang=en_us&edition=fundamental","pubTime":"2026-09-15 16:44","pubTimestamp":1789461842,"startTime":"0","endTime":"0","summary":"Zhejiang Hisun Pharmaceutical's  subsidiary, Zhejiang Hisun Animal Health Products, received veterinary drug approval certificates from China's Ministry of Agriculture and Rural Affairs for its Compound Fipronil, Praziquantel and Moxidectin Topical Solution, according to Shanghai bourse filing on Tuesday.THe drug is used to prevent and treat internal and external parasitic infections in cats, including flea and tick infections.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0188","BK0060","BK0239","BK0028","600267"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667657006","title":"FDA Allows Hisun Pharmaceutical's Glucosamine Hydrochloride in US Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2667657006","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667657006?lang=en_us&edition=fundamental","pubTime":"2026-09-14 18:38","pubTimestamp":1789382283,"startTime":"0","endTime":"0","summary":"The U.S. Food and Drug Administration recognized Zhejiang Hisun Pharmaceutical's  glucosamine hydrochloride product as safe, according to a Saturday filing with the Shanghai bourse.The product, manufactured by subsidiary Zhejiang Yunsheng Synthetic Biology, will be allowed for marketing in the U.S. and can be sold as a safe dietary ingredient, the filing said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","BK0028","BK0060","600267","BK4585","LABU","BK0188","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199629630","title":"Hisun Charts New Course at BIOHK2026: Embracing Biomanufacturing and Expanding into Wellness Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=1199629630","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199629630?lang=en_us&edition=fundamental","pubTime":"2026-09-14 10:50","pubTimestamp":1789354253,"startTime":"0","endTime":"0","summary":"The 5th Hong Kong International Bio-Tech Forum and Exhibition (BIOHK2026) drew to a close on September 12, 2026, having convened at the Hong Kong Convention and Exhibition Centre from September 9th....","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","600267","BK0060","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138997485","title":"Hisun's Subsidiary Secures US Self-GRAS Approval for Glucosamine Hydrochloride","url":"https://stock-news.laohu8.com/highlight/detail?id=1138997485","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138997485?lang=en_us&edition=fundamental","pubTime":"2026-09-11 18:08","pubTimestamp":1789121293,"startTime":"0","endTime":"0","summary":"Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SH) has announced that its wholly-owned subsidiary, Zhejiang Yunsheng Synthetic Biology Co., Ltd., has successfully passed the US Self-GRAS...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["600267","BK0239","BK0188","BK0028","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665328296","title":"Zhejiang Hisun Pharmaceutical Subsidiary Gets China Nod for Anti-Parasite Drug for Cats","url":"https://stock-news.laohu8.com/highlight/detail?id=2665328296","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665328296?lang=en_us&edition=fundamental","pubTime":"2026-09-08 15:39","pubTimestamp":1788853144,"startTime":"0","endTime":"0","summary":"Zhejiang Hisun Pharmaceutical  subsidiary Zhejiang Hisun Animal Health Products received a veterinary drug registration certificate from the Ministry of Agriculture and Rural Affairs for its fipronil, praziquantel, and moxidectin compound drug, according to a Tuesday disclosure to the Shanghai bourse.The drug helps prevent parasitic infections in cats, including fleas and ticks, heartworm, and gastrointestinal nematodes, and as an adjunctive treatment for flea allergy dermatitis, the filing said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600267","BK0060","BK0028","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186214666","title":"Zhejiang Hisun Pharmaceutical Schedules Investor Meeting for First-Half 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1186214666","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186214666?lang=en_us&edition=fundamental","pubTime":"2026-08-25 21:21","pubTimestamp":1787664083,"startTime":"0","endTime":"0","summary":"On August 25, Zhejiang Hisun Pharmaceutical Co.,Ltd. announced that its investor communication session covering the first-half 2026 financial results is set to take place on September 3, 2026, from...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["600267","BK0060","BK0028","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662381357","title":"Zhejiang Hisun Pharmaceutical H1 Net Profit up 112.8% Y/Y","url":"https://stock-news.laohu8.com/highlight/detail?id=2662381357","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662381357?lang=en_us&edition=fundamental","pubTime":"2026-08-25 17:47","pubTimestamp":1787651256,"startTime":"0","endTime":"0","summary":"BRIEF-Zhejiang Hisun Pharmaceutical H1 Net Profit Up 112.8% Y/YAug 25 (Reuters)-Zhejiang Hisun Pharmaceutical Co Ltd600267.SS:H1 NET PROFIT UP 112.8% Y/YSource textFurther company coverage:600267.SS","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nL4N44M0KB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","600267","BK0188","BK0060","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656153511","title":"Zhejiang Hisun Pharmaceutical Wins Pre-Bids for Five Drugs Under China Procurement System","url":"https://stock-news.laohu8.com/highlight/detail?id=2656153511","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656153511?lang=en_us&edition=fundamental","pubTime":"2026-08-04 16:16","pubTimestamp":1785831373,"startTime":"0","endTime":"0","summary":"Zhejiang Hisun Pharmaceutical  and subsidiary Hanhui Pharmaceutical won pre-bids for five products under China's drug procurement program, according to a Tuesday filing with the Shanghai bourse.Three of the drugs are antibiotic injections, including imipenem and cilastatin sodium, vancomycin hydrochloride, and teicoplanin.Two other products, tacrolimus for injection and epirubicin hydrochloride, are chemotherapy drugs.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0060","BK0239","600267","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134729119","title":"Zhejiang Hisun Pharmaceutical Secures Tentative Selection for Five Products in National Bulk Drug Procurement","url":"https://stock-news.laohu8.com/highlight/detail?id=1134729119","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134729119?lang=en_us&edition=fundamental","pubTime":"2026-08-03 15:53","pubTimestamp":1785743637,"startTime":"0","endTime":"0","summary":"Zhejiang Hisun Pharmaceutical Co.,Ltd. (600267.SH) announced that on July 31, 2026, the company and its wholly-owned subsidiary, Hanhui Pharmaceutical Co., Ltd., participated in the bidding process...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["600267","BK0060","BK0028","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654090579","title":"Zhejiang Hisun Pharmaceutical Receives US FDA Abbreviated New Drug Application Approval for Leukemia Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2654090579","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654090579?lang=en_us&edition=fundamental","pubTime":"2026-07-27 15:34","pubTimestamp":1785137689,"startTime":"0","endTime":"0","summary":"Zhejiang Hisun Pharmaceutical  received an abbreviated new drug application approval from the U.S. Food and Drug Administration for its fludarabine phosphate injection, according to a Saturday filing with the Shanghai bourse.The injection is indicated for the treatment of adult B-cell chronic lymphocytic leukemia for patients unresponsive to at least one prior alkylating agent-containing therapy or whose disease has progressed during treatment.Global sales of the injection reached $23.5 million in 2025, according to market data cited in the filing.Hisun has invested 10 million yuan for research and development of the drug.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0188","BK0060","BK0028","BK4585","BK4588","600267","BK0239","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153375470","title":"Zhejiang Hisun Pharmaceutical Subsidiary Obtains US FDA Clearance for Generic Cancer Drug Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=1153375470","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153375470?lang=en_us&edition=fundamental","pubTime":"2026-07-24 16:58","pubTimestamp":1784883503,"startTime":"0","endTime":"0","summary":"Zhejiang Hisun Pharmaceutical Co.,Ltd. (600267.SH) has announced that its wholly-owned subsidiary, Hisun Pharmaceutical (Hangzhou) Co., Ltd., has received notification from the U.S. Food and Drug...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","600267","BK0239","BK4588","BK0060","BK0188","BK0028","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650643189","title":"Zhejiang Hisun Pharmaceutical Sees H1 Net Profit up 100.62%-117.34% Y/Y","url":"https://stock-news.laohu8.com/highlight/detail?id=2650643189","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650643189?lang=en_us&edition=fundamental","pubTime":"2026-07-10 17:48","pubTimestamp":1783676929,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260710:nL4N43C0O4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["600267","BK0239","BK0028","BK0060","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647453735","title":"Zhejiang Hisun Pharmaceutical Gets Approval for Cytomegalovirus Medication","url":"https://stock-news.laohu8.com/highlight/detail?id=2647453735","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647453735?lang=en_us&edition=fundamental","pubTime":"2026-06-30 18:30","pubTimestamp":1782815413,"startTime":"0","endTime":"0","summary":"China's drug regulator approved Zhejiang Hisun Pharmaceutical's (SHA:600267) letermovir antiviral active ingredient, according to a Tuesday filing with the Shanghai bourse.The drug is indicated for cytomegalovirus prevention and cure in adults and children weighing 6 kilograms or more.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0028","BK0060","BK0239","BK0188","600267"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182717769","title":"Zhejiang Hisun Pharmaceutical Receives Approval for Letermovir Active Ingredient","url":"https://stock-news.laohu8.com/highlight/detail?id=1182717769","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182717769?lang=en_us&edition=fundamental","pubTime":"2026-06-29 16:54","pubTimestamp":1782723260,"startTime":"0","endTime":"0","summary":"An announcement from Zhejiang Hisun Pharmaceutical Co.,Ltd. (ASX: 600267) indicates that the company has recently obtained the \"Chemical Drug Substance Marketing Authorization Approval Notice\" for...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["600267","BK0028","BK0188","BK0239","BK0060","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168403352","title":"Zhejiang Hisun Pharmaceutical's Finerenone API Receives Market Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1168403352","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168403352?lang=en_us&edition=fundamental","pubTime":"2026-06-11 15:54","pubTimestamp":1781164462,"startTime":"0","endTime":"0","summary":"Zhejiang Hisun Pharmaceutical Co.,Ltd. (ASX: 600267) has announced that it recently received the \"Chemical Active Pharmaceutical Ingredient Marketing Application Approval Notice\" for finerenone from...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0060","BK0239","600267","BK0028","BK0188","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637367084","title":"Hisun Pharmaceutical Clinches NMPA Drug Registration for Prostate Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2637367084","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637367084?lang=en_us&edition=fundamental","pubTime":"2026-05-22 12:21","pubTimestamp":1779423692,"startTime":"0","endTime":"0","summary":"Zhejiang Hisun Pharmaceutical (SHA:600267) received a drug registration certificate from China's National Medical Products Administration for its apalutamide tablets, according to a Friday disclosure on the Shanghai bourse.The drug is used to treat prostate cancer.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0028","BK0239","BK0188","BK0060","600267"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140817235","title":"Hisun Pharmaceutical Obtains Approval for Apalutamide Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=1140817235","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140817235?lang=en_us&edition=fundamental","pubTime":"2026-05-21 17:04","pubTimestamp":1779354281,"startTime":"0","endTime":"0","summary":"Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SH) has announced the receipt of a drug registration certificate for Apalutamide Tablets from the National Medical Products Administration. The tablets...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["600267","BK0060","BK0188","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630914364","title":"BRIEF-Zhejiang Hisun Pharmaceutical Q1 Net Profit Up 83.1% Y/Y","url":"https://stock-news.laohu8.com/highlight/detail?id=2630914364","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630914364?lang=en_us&edition=fundamental","pubTime":"2026-04-27 17:44","pubTimestamp":1777283081,"startTime":"0","endTime":"0","summary":"BRIEF-Zhejiang Hisun Pharmaceutical Q1 Net Profit Up 83.1% Y/YApril 27 (Reuters) - Zhejiang Hisun Pharmaceutical Co Ltd 600267.SS:Q1 NET PROFIT UP 83.1% Y/YSource textFurther company coverage: 600267.SS (Reporting by Beijing Newsroom) ((yukun.zhang@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nL4N41A0PC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","BK0188","BK0060","600267","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1792683551932,"stockEarnings":[{"period":"1week","weight":0.228},{"period":"1month","weight":0.1752},{"period":"3month","weight":0.1567},{"period":"6month","weight":0.2519},{"period":"1year","weight":0.3467},{"period":"ytd","weight":0.4393}],"compareEarnings":[{"period":"1week","weight":-0.0144},{"period":"1month","weight":-0.06},{"period":"3month","weight":-0.0422},{"period":"6month","weight":-0.0899},{"period":"1year","weight":-0.0519},{"period":"ytd","weight":-0.0645}],"compareStock":{"symbol":"000001.SH","name":"SSE Comp"},"companyName":"浙江海正药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"48826人(较上一季度增加2.42%)","perCapita":"24173股","listingDate":"2000-07-25","address":"浙江省台州市椒江区外沙路46号","registeredCapital":"118027万元","survey":"　　浙江海正药业股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是海博麦布片（赛斯美）、注射用哌拉西林钠他唑巴坦钠（特治星）、盐酸米诺环素胶囊（玫满）、茚达特罗格隆溴铵吸入粉雾剂（杰润）、注射用丝裂霉素、瑞舒伐他汀钙片（海舒严）、注射用亚胺培南西司他丁钠（俊特）、米尔贝肟吡喹酮片（海乐妙）、丁二磺酸腺苷蛋氨酸肠溶片（喜美欣）、英夫马芬净。","listedPrice":11.83},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Zhejiang Hisun Pharmaceutical Co.,Ltd.(600267),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Zhejiang Hisun Pharmaceutical Co.,Ltd.(600267) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Zhejiang Hisun Pharmaceutical Co.,Ltd.,600267,Zhejiang Hisun Pharmaceutical Co.,Ltd.股票,Zhejiang Hisun Pharmaceutical Co.,Ltd.股票老虎,Zhejiang Hisun Pharmaceutical Co.,Ltd.股票老虎国际,Zhejiang Hisun Pharmaceutical Co.,Ltd.行情,Zhejiang Hisun Pharmaceutical Co.,Ltd.股票行情,Zhejiang Hisun Pharmaceutical Co.,Ltd.股价,Zhejiang Hisun Pharmaceutical Co.,Ltd.股市,Zhejiang Hisun Pharmaceutical Co.,Ltd.股票价格,Zhejiang Hisun Pharmaceutical Co.,Ltd.股票交易,Zhejiang Hisun Pharmaceutical Co.,Ltd.股票购买,Zhejiang Hisun Pharmaceutical Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Zhejiang Hisun Pharmaceutical Co.,Ltd.(600267),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Zhejiang Hisun Pharmaceutical Co.,Ltd.(600267) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}